(Q45877987)

17 December 2017

title

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis (English)

1 reference

17 December 2017

0 references

1 reference

ChEBI release 2020-05-28

Yuki Fujii

1

1 reference

17 December 2017

Masanori Abe

2

1 reference

17 December 2017

Terumi Higuchi

3

1 reference

17 December 2017

Mari Mizuno

4

1 reference

17 December 2017

Hiroko Suzuki

5

1 reference

17 December 2017

Shiro Matsumoto

6

1 reference

17 December 2017

Midori Ito

7

1 reference

17 December 2017

Noriaki Maruyama

8

1 reference

17 December 2017

Kazuyoshi Okada

9

1 reference

17 December 2017

Masayoshi Soma

10

1 reference

17 December 2017

language of work or name

English

0 references

publication date

7 January 2013

1 reference

17 December 2017

Expert Opinion on Pharmacotherapy

published in

1 reference

17 December 2017

volume

14

1 reference

17 December 2017

issue

3

1 reference

17 December 2017

page(s)

259-267

1 reference

17 December 2017

Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Oral antihyperglycemic agents and renal disease: new agents, new concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Carboxyl-glucuronidation of mitiglinide by human UDP-glucuronosyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Alogliptin: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Standards of medical care in diabetes--2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Stringent glycaemic control prolongs survival in diabetic patients with end-stage renal disease on haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

DPP-4 inhibitors and their potential role in the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Antihyperglycaemic therapy in elderly patients with type 2 diabetes: potential role of incretin mimetics and DPP-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.761690

Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection

21 January 2018

1 reference

23 October 2023

https://opencitations.net/index/coci/api/v1/citations/10.1681/ASN.2006070772

Identifiers

DOI

10.1517/14656566.2013.761690

1 reference

17 December 2017

PubMed ID

23289982

1 reference

17 December 2017